Therefore, previous studies have attempted to use lapatinib (HER2 tyrosine kinase inhibitor), pertuzumab or trastuzumab (HER2 dimerization inhibitors), and trastuzumab emtansine or trastuzumab deruxtecan (HER2 monoclonal antibody–drug conjugates) to treat patients with HER2-expressing ovarian cancer [15]. Here, ERBB2 is linked to ovarian cancer.